Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - klofarabin - koncentrat till infusionsvätska, lösning - 1 mg/ml - klofarabin 1 mg aktiv substans

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

wyeth europa ltd - gemtuzumab ozogamicin - leukemi, myeloid, akut - antineoplastiska medel - re-induktion behandling av cd33-positiva aml vuxna patienter i första återfall som inte är kandidater för andra intensiva re-induktion cytostatika kurer (e. hög dos ara-c) och uppfylla minst ett av följande kriterier: varaktighet av första remission 60 år.

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

koanaa healthcare gmbh - klofarabin - koncentrat till infusionsvätska, lösning - 1 mg/ml - klofarabin 1 mg aktiv substans

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunstimulatorer, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

seacross pharma (europe) limited - plerixafor - injektionsvätska, lösning - 20 mg/ml - plerixafor 20 mg aktiv substans

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

cheplapharm arzneimittel gmbh - all-rac-fytomenadion - injektionsvätska, lösning - 10 mg/ml - all-rac-fytomenadion 10 mg aktiv substans - fytomenadion

Ruotsi - ruotsi - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - all-rac-fytomenadion - injektionsvätska, lösning - 10 mg/ml - all-rac-fytomenadion 10 mg aktiv substans

Euroopan unioni - ruotsi - EMA (European Medicines Agency)

recordati rare diseases - tokofersolan - cholestasis; vitamin e deficiency - vitaminer - vedrop är indicerat i-e-vitaminbrist på grund av mag malabsorption i pediatriska patienter som lider av medfödd kronisk kolestas eller ärftlig kronisk kolestas, från födseln (i termen nyfödda) till 16 eller 18 år, beroende på region.